Sun's anti-IL23 mAb meets in Phase III psoriasis trials

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said anti-IL-23 antibody tildrakizumab ( MK-3222) met the co-primary endpoints in two Phase III trials to treat moderate to severe plaque psoriasis. The molecule is specific for the p19 subunit of

Read the full 370 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE